315 related articles for article (PubMed ID: 10648652)
1. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease.
Camps P; Cusack B; Mallender WD; El Achab RE; Morral J; Muñoz-Torrero D; Rosenberry TL
Mol Pharmacol; 2000 Feb; 57(2):409-17. PubMed ID: 10648652
[TBL] [Abstract][Full Text] [Related]
2. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates.
Dvir H; Wong DM; Harel M; Barril X; Orozco M; Luque FJ; Muñoz-Torrero D; Camps P; Rosenberry TL; Silman I; Sussman JL
Biochemistry; 2002 Mar; 41(9):2970-81. PubMed ID: 11863435
[TBL] [Abstract][Full Text] [Related]
3. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases.
Galdeano C; Viayna E; Sola I; Formosa X; Camps P; Badia A; Clos MV; Relat J; Ratia M; Bartolini M; Mancini F; Andrisano V; Salmona M; Minguillón C; González-Muñoz GC; Rodríguez-Franco MI; Bidon-Chanal A; Luque FJ; Muñoz-Torrero D
J Med Chem; 2012 Jan; 55(2):661-9. PubMed ID: 22185619
[TBL] [Abstract][Full Text] [Related]
4. Effect of huprine X on β-amyloid, synaptophysin and α7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice.
Hedberg MM; Clos MV; Ratia M; Gonzalez D; Lithner CU; Camps P; Muñoz-Torrero D; Badia A; Giménez-Llort L; Nordberg A
Neurodegener Dis; 2010; 7(6):379-88. PubMed ID: 20689242
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors.
Camps P; Formosa X; Muñoz-Torrero D; Petrignet J; Badia A; Clos MV
J Med Chem; 2005 Mar; 48(6):1701-4. PubMed ID: 15771413
[TBL] [Abstract][Full Text] [Related]
6. The pharmacology of novel acetylcholinesterase inhibitors, (+/-)-huprines Y and X, on the Torpedo electric organ.
Ros E; Aleu J; Gómez de Aranda I; Muñoz-Torrero D; Camps P; Badia A; Marsal J; Solsona C
Eur J Pharmacol; 2001 Jun; 421(2):77-84. PubMed ID: 11399262
[TBL] [Abstract][Full Text] [Related]
7. Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates.
Viayna E; Gómez T; Galdeano C; Ramírez L; Ratia M; Badia A; Clos MV; Verdaguer E; Junyent F; Camins A; Pallàs M; Bartolini M; Mancini F; Andrisano V; Arce MP; Rodríguez-Franco MI; Bidon-Chanal A; Luque FJ; Camps P; Muñoz-Torrero D
ChemMedChem; 2010 Nov; 5(11):1855-70. PubMed ID: 20859987
[TBL] [Abstract][Full Text] [Related]
8. Huprine derivatives as sub-nanomolar human acetylcholinesterase inhibitors: from rational design to validation by X-ray crystallography.
Ronco C; Carletti E; Colletier JP; Weik M; Nachon F; Jean L; Renard PY
ChemMedChem; 2012 Mar; 7(3):400-5. PubMed ID: 22052791
[No Abstract] [Full Text] [Related]
9. Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy.
Mezeiova E; Korabecny J; Sepsova V; Hrabinova M; Jost P; Muckova L; Kucera T; Dolezal R; Misik J; Spilovska K; Pham NL; Pokrievkova L; Roh J; Jun D; Soukup O; Kaping D; Kuca K
Molecules; 2017 Jul; 22(8):. PubMed ID: 28788095
[TBL] [Abstract][Full Text] [Related]
10. Nonequilibrium analysis alters the mechanistic interpretation of inhibition of acetylcholinesterase by peripheral site ligands.
Szegletes T; Mallender WD; Rosenberry TL
Biochemistry; 1998 Mar; 37(12):4206-16. PubMed ID: 9521743
[TBL] [Abstract][Full Text] [Related]
11. New huprine derivatives functionalized at position 9 as highly potent acetylcholinesterase inhibitors.
Ronco C; Foucault R; Gillon E; Bohn P; Nachon F; Jean L; Renard PY
ChemMedChem; 2011 May; 6(5):876-88. PubMed ID: 21344648
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of the anticholinesterase activity of two new tacrine-huperzine A hybrids.
Alcalá Mdel M; Vivas NM; Hospital S; Camps P; Muñoz-Torrero D; Badia A
Neuropharmacology; 2003 May; 44(6):749-55. PubMed ID: 12681373
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship of Huprine derivatives as human acetylcholinesterase inhibitors.
Ronco C; Sorin G; Nachon F; Foucault R; Jean L; Romieu A; Renard PY
Bioorg Med Chem; 2009 Jul; 17(13):4523-36. PubMed ID: 19473849
[TBL] [Abstract][Full Text] [Related]
14. Screening of new huprines--inhibitors of acetylcholinesterases by electrospray ionization ion trap mass spectrometry.
Ziemianin A; Ronco C; Dolé R; Jean L; Renard PY; Lange CM
J Pharm Biomed Anal; 2012 Nov; 70():1-5. PubMed ID: 22677656
[TBL] [Abstract][Full Text] [Related]
15. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.
Camps P; El Achab R ; Morral J; Muñoz-Torrero D; Badia A; Baños JE; Vivas NM; Barril X; Orozco M; Luque FJ
J Med Chem; 2000 Nov; 43(24):4657-66. PubMed ID: 11101357
[TBL] [Abstract][Full Text] [Related]
16. Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
Pérez-Areales FJ; Di Pietro O; Espargaró A; Vallverdú-Queralt A; Galdeano C; Ragusa IM; Viayna E; Guillou C; Clos MV; Pérez B; Sabaté R; Lamuela-Raventós RM; Luque FJ; Muñoz-Torrero D
Bioorg Med Chem; 2014 Oct; 22(19):5298-307. PubMed ID: 25156301
[TBL] [Abstract][Full Text] [Related]
17. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).
Dodds HM; Rivory LP
Mol Pharmacol; 1999 Dec; 56(6):1346-53. PubMed ID: 10570064
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
Badia A; Baños JE; Camps P; Contreras J; Görbig DM; Muñoz-Torrero D; Simón M; Vivas NM
Bioorg Med Chem; 1998 Apr; 6(4):427-40. PubMed ID: 9597187
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
Camps P; El Achab R; Görbig DM; Morral J; Muñoz-Torrero D; Badia A; Eladi Baños J; Vivas NM; Barril X; Orozco M; Luque FJ
J Med Chem; 1999 Aug; 42(17):3227-42. PubMed ID: 10464010
[TBL] [Abstract][Full Text] [Related]
20. Hopeahainol A binds reversibly at the acetylcholinesterase (AChE) peripheral site and inhibits enzyme activity with a novel higher order concentration dependence.
Rosenberry TL; Martin PK; Nix AJ; Wildman SA; Cheung J; Snyder SA; Tan RX
Chem Biol Interact; 2016 Nov; 259(Pt B):78-84. PubMed ID: 27297626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
